A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 410 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 May 7, 2025 Hope and Challenge: The NCI Annual Plan and Budget Proposal for... September 24, 2018 2026 ESMO TAT Honorary Award Recipient Announced February 3, 2026 The UK Government’s spending review: Time to invest in the future... October 20, 2020 Load more HOT NEWS Touching a nerve: How neuroscience could advance our understanding of cancer FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer Sugar and cancer – what you need to know Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer
